Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: The news release does not mention costs. While a new therapy may not have an established price, the release could have stated “no price is available for this drug.” What would be even better is some context for what women suffering from postpartum pay typically for counseling and medications. The release notes that  there was a reduction in depressive symptoms of 17 points for those on the drug, and 12.8 for those in the placebo group based on the Hamilton Depression Rating Scale. The absolute reduction in the rating scale is given for each group. This information would have been much more helpful if the release also clarified the magnitude of the scale and whether a 4.2-point difference is clinically meaningful. The release contains one somewhat vague sentence on harms. The most common (≥10% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence. Readers would also be interested in details on whether the drug is safe for nursing infants. That’s not mentioned. The double-blinded randomized trials are described in detail and readers are able to judge the quality of the evidence. The published study includes an important limitation of the research that’s not mentioned in the release: The trials assessed women for only 30 days; the effects of the treatment beyond 30 days are “unknown.” There is no disease mongering. The release explains how common postpartum depression is worldwide. The release notes that Sage Therapeutics funded the research. Sage Therapeutics is the developer of brexanolone injection and sponsor of the trials. A New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation. The FDA has assigned a Prescription Drug User Fee Act target date of December 19, 2018. What the release doesn’t tell us is that both quoted researchers disclosed financial ties with Sage Therapeutics. This information was included in the studies published in the Lancet. SM-B reports personal fees from MedScape and grants from Sage Therapeutics, awarded to the University of North Carolina … DRR reports personal fees and has stock options in Sage Therapeutics…. The release mentions that women currently can receive antidepressants for postpartum depression, but that the new drug being studied goes to work relieving symptoms faster than traditional antidepressants — days rather than weeks. The release notes that the drug is currently under FDA review, with a decision on its approval expected by the end of the year. The release notes that the new drug would be a novel treatment for postpartum depression, if approved. There is no unjustifiable language.

Output: Newly Published Results Show Investigational Treatment Brexanolone Consistently Reduced Depressive Symptoms Across Three Postpartum Depression Trials, Supporting Submission for FDA Approval


Input: Consider Input: While the story does describe the cost of stenting, it does not provide the cost of the medication for comparison. The story does give the rate of heart attack or death as 19% within 7 years for both the stent and the medication group. Although the study mentions the risk of clotting with drug-coated stents, this is not adequate information on harms. Furthermore, the study does not mention any possible harms of medication. The story adequately describes the design of the current study. The story does not exaggerate the seriousness or prevalence of heart disease. Furthermore, the story clearly states that this study was done on patients at low risk, that is, those with stable heart disease. The story only quotes one cardiologist not associated with the study and gives no rationale for why he was chosen. (Is it because he's in New York and readily available?) The story could have quoted other clinicians or experts who could have provided some valuable perspective on the impact of this new development on the management of heart disease. The story does mention medication as the alternative to stenting. The story clearly states that stenting is very common in the U.S. The story clearly states that stenting is not a new idea. Because the story quotes the lead author of the study and one physician who is not related to the study, the reader can assume the story did not rely on a press release as the sole source of information.

Output: Heart study: Most angioplasties not needed


Input: Consider Input: “This disease has just occurred in Thailand. We’ve never had it in the past,” director-general of the Department of Livestock Development, Sorawit Thanito, said on Thursday. The government has quarantined sick horses to limit the spread of the disease, Sorawit said. At least 131 horses have died across four provinces, latest government data showed. “We have to investigate how this virus got to Thailand,” he said, adding that the government was notified in late March of AHS in the country. Horses suffering from the illness can have fevers of over 39 Celsius, difficulty breathing and bleeding in the eyes. There have been no reported cases of AHS in humans and it was not related to the outbreak of the new coronavirus, Sorawit said. The World Organization for Animal Health (OIE) suspended Thailand’s status as an “AHS Free Country” on March 27. AHS is endemic in the central tropical regions of Africa, from where it spreads regularly to Southern Africa and occasionally to North Africa, according to the OIE. Myanmar and Kyrgyzstan had their AHS-free statuses suspended in 2018.


Output: Thailand hit by African Horse Sickness, killing over 100 horses.